Previous Close | 1.1800 |
Open | 1.1800 |
Bid | 1.1200 x 3000 |
Ask | 1.2400 x 4000 |
Day's Range | 1.1100 - 1.2000 |
52 Week Range | 0.9010 - 4.5900 |
Volume | 778,545 |
Avg. Volume | 700,730 |
Market Cap | 90M |
Beta (5Y Monthly) | 1.46 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.1190 |
Earnings Date | Nov 7, 2019 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 7.00 |
We at Insider Monkey have gone over 752 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds' and investors' portfolio positions as of September 30th. In this article, we look at what those funds think of Aduro BioTech Inc (NASDAQ:ADRO) based on that […]
If you own shares in Aduro BioTech, Inc. (NASDAQ:ADRO) then it's worth thinking about how it contributes to the...
Aduro Biotech (ADRO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Aduro Biotech, Inc. (ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL) pathways for the treatment of cancer, autoimmune and inflammatory diseases, today announced that its license partner, Merck & Co., Inc. (known as MSD outside the United States and Canada), presented data from an ongoing Phase 1 clinical trial of MK-5890, an anti-CD27 agonist. MK-5890 is being evaluated as monotherapy and in combination with KEYTRUDA® (pembrolizumab), an approved anti-PD-1 antibody, in adults with advanced solid tumors.
Aduro's (ADRO) loss misses estimates in Q3 while revenues almost match the mark.
Aduro Biotech (ADRO) delivered earnings and revenue surprises of -13.04% and 5.47%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
BERKELEY, Calif., Nov. 07, 2019 -- Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of.
Steve Isaacs became the CEO of Aduro BioTech, Inc. (NASDAQ:ADRO) in 2008. This report will, first, examine the CEO...
Aduro Biotech, Inc. (ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL) pathways for the treatment of cancer, autoimmune and inflammatory diseases, today announced that two abstracts have been accepted for presentation at the Society for Immunotherapy of Cancer 34th Annual Meeting (SITC 2019) in National Harbor, MD from November 6 – 10, 2019. The abstracts, which will be presented in a poster session, include a clinical trial in progress description of the Phase 2 study of ADU-S100 (MIW815) in combination with KEYTRUDA® (pembrolizumab) as a first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC), as well as nonclinical data on the role of TNF-alpha signaling on STING agonists.
BERKELEY, Calif., Sept. 30, 2019 -- Aduro Biotech, Inc. (NASDAQ: ADRO) today announced that Andrea van Elsas, chief scientific officer of Aduro, is scheduled to present at the.
The big shareholder groups in Aduro BioTech, Inc. (NASDAQ:ADRO) have power over the company. Generally speaking, as a...
BERKELEY, Calif., Sept. 04, 2019 -- Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of.
BERKELEY, Calif., Sept. 03, 2019 -- Aduro Biotech, Inc. (NASDAQ: ADRO) today announced that Stephen T. Isaacs, chairman, president and chief executive officer of Aduro, is.
Aduro Biotech (ADRO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be...
Aduro (ADRO) suffers wider-than-expected loss in the second quarter while revenues match estimates.
BERKELEY, Calif., Aug. 01, 2019 -- Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of.
Aduro Biotech (ADRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AbbVie (ABBV) buys Mavupharma to develop novel treatments for cancer using the latter's STING signaling pathway.
Aduro (ADRO) presents updated data from an ongoing phase Ib study evaluating its STING agonist, ADU-S100 in combination with Novartis' checkpoint inhibitor.
Aduro Biotech, Inc. (ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL) pathways for the treatment of cancer, autoimmune and inflammatory diseases, today announced the presentation of data from an ongoing Phase 1b clinical trial in collaboration with Novartis. Aduro’s ADU-S100 (MIW815), a novel STING pathway activator, is being evaluated in combination with Novartis’ spartalizumab (PDR001), an investigational anti-PD-1 monoclonal antibody, in patients with advanced solid tumors or lymphomas.
Aduro Biotech, Inc. (ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL) pathways for the treatment of cancer, autoimmune and inflammatory diseases, today announced that the company will host and webcast an investor event on Monday, June 3, 2019 at 6:30 am CDT in Chicago, IL. Guest speaker, Dr. Funda Meric-Bernstam of MD Anderson Cancer Center, is a principal investigator for the Phase 1 study of STING pathway activator ADU-S100 (MIW815) in combination with spartalizumab (PDR001), Novartis’ investigational anti-PD-1 monoclonal antibody, in patients with advanced/metastatic solid tumors or lymphomas.
Aduro Biotech, Inc. (ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL) pathways for the treatment of cancer, autoimmune and inflammatory diseases, today provided an update on its clinical development programs for BION-1301, a first-in-class humanized IgG4 monoclonal antibody that fully blocks APRIL binding to both the BCMA and TACI receptors.
Aduro (ADRO) suspends the BION-1301 program for MM in Q1 due to severe competition.